Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.

EMBO molecular medicine - 1 Oct 2014

Melotti Alice, Mas Christophe, Kuciak Monika, Lorente-Trigos Aiala, Borges Isabel, Ruiz i Altaba Ariel

Abstract excerpt

Constitutive activation of canonical WNT-TCF signaling is implicated in multiple diseases, including intestine and lung cancers, but there are no WNT-TCF antagonists in clinical use. We have performed a repositioning screen for WNT-TCF response blockers aiming to recapitulate the genetic blockade afforded by dominant-negative TCF. We report that Ivermectin inhibits the expression of WNT-TCF targets, mimicking...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HT29 Cells
Share to Insecticides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ivermectin

Share to Lactones

Share to Macrocyclic Compounds

Share to TCF Transcription Factors

Share to Wnt Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 25143352
DOI: 10.15252/emmm.201404084
PMCID: PMC4287931

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.PMID 25143352Read ↗

Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replicationSemantic proximity Read ↗

Computational Drug Repositioning and Experimental Validation of Ivermectin in Treatment of Gastric CancerSemantic proximity Read ↗

A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent CancersSemantic proximity Read ↗

Wnt/?-catenin-pathway as a molecular target for future anti-cancer therapeuticsSemantic proximity Read ↗

Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancerSemantic proximity Read ↗

High-Throughput Screening for Discovering Small Molecules Capable of Increasing the Wnt/β-Catenin Signaling Pathway to Promote Hair and Nail GrowthSemantic proximity Read ↗

Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axesSemantic proximity Read ↗

IMU1003, an atrarate derivative, inhibits Wnt/β-catenin signaling.Semantic proximity Read ↗

Resistomycin Inhibits Wnt/β-Catenin Signaling to Induce the Apoptotic Death of Human Colorectal Cancer CellsSemantic proximity Read ↗

Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivoSemantic proximity Read ↗

Visualizing Antineoplastic Activity with a Whole Organism Drosophila melanogaster ScreenSemantic proximity Read ↗

Prospective mode of action of Ivermectin: SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.